Enzolytics Stock Performance
| ENZC Stock | USD 0.0006 0.0001 20.00% |
Enzolytics holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.0316, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Enzolytics are expected to decrease at a much lower rate. During the bear market, Enzolytics is likely to outperform the market. Use Enzolytics potential upside and the relationship between the skewness and price action indicator , to analyze future returns on Enzolytics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Enzolytics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Enzolytics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Enzolytics |
Enzolytics Relative Risk vs. Return Landscape
If you would invest 0.03 in Enzolytics on November 3, 2025 and sell it today you would earn a total of 0.03 from holding Enzolytics or generate 100.0% return on investment over 90 days. Enzolytics is currently generating 4.328% in daily expected returns and assumes 27.2769% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Enzolytics, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enzolytics Target Price Odds to finish over Current Price
The tendency of Enzolytics Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0006 | 90 days | 0.0006 | roughly 2.02 |
Based on a normal probability distribution, the odds of Enzolytics to move above the current price in 90 days from now is roughly 2.02 (This Enzolytics probability density function shows the probability of Enzolytics Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Enzolytics has a beta of -0.0316 suggesting as returns on the benchmark increase, returns on holding Enzolytics are expected to decrease at a much lower rate. During a bear market, however, Enzolytics is likely to outperform the market. In addition to that Enzolytics has an alpha of 3.6275, implying that it can generate a 3.63 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Enzolytics Price Density |
| Price |
Predictive Modules for Enzolytics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Enzolytics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Enzolytics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Enzolytics is not an exception. The market had few large corrections towards the Enzolytics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Enzolytics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Enzolytics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 3.63 | |
β | Beta against Dow Jones | -0.03 | |
σ | Overall volatility | 0.0001 | |
Ir | Information ratio | 0.14 |
Enzolytics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Enzolytics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Enzolytics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Enzolytics is way too risky over 90 days horizon | |
| Enzolytics has some characteristics of a very speculative penny stock | |
| Enzolytics appears to be risky and price may revert if volatility continues | |
| Enzolytics has high likelihood to experience some financial distress in the next 2 years | |
| Enzolytics currently holds 233.12 K in liabilities. Enzolytics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Enzolytics until it has trouble settling it off, either with new capital or with free cash flow. So, Enzolytics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enzolytics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enzolytics to invest in growth at high rates of return. When we think about Enzolytics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 190 K. Net Loss for the year was (57.28 K) with profit before overhead, payroll, taxes, and interest of 52.81 K. | |
| Latest headline from cnbc.com: Healthy Returns Botox, Trulicity among 15 drugs added to Medicare price negotiations |
Enzolytics Fundamentals Growth
Enzolytics Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Enzolytics, and Enzolytics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enzolytics Pink Sheet performance.
| Return On Asset | -7.05 | |||
| Operating Margin | (19.24) % | |||
| Current Valuation | 71.57 M | |||
| Shares Outstanding | 2.44 B | |||
| Price To Sales | 2,083 X | |||
| Revenue | 190 K | |||
| EBITDA | (886.77 K) | |||
| Cash And Equivalents | 5.76 K | |||
| Total Debt | 233.12 K | |||
| Book Value Per Share | (0.63) X | |||
| Cash Flow From Operations | 4.89 M | |||
| Earnings Per Share | (4.76) X | |||
| Total Asset | 3.31 M | |||
About Enzolytics Performance
By analyzing Enzolytics' fundamental ratios, stakeholders can gain valuable insights into Enzolytics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enzolytics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enzolytics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Enzolytics performance evaluation
Checking the ongoing alerts about Enzolytics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Enzolytics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enzolytics is way too risky over 90 days horizon | |
| Enzolytics has some characteristics of a very speculative penny stock | |
| Enzolytics appears to be risky and price may revert if volatility continues | |
| Enzolytics has high likelihood to experience some financial distress in the next 2 years | |
| Enzolytics currently holds 233.12 K in liabilities. Enzolytics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Enzolytics until it has trouble settling it off, either with new capital or with free cash flow. So, Enzolytics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enzolytics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enzolytics to invest in growth at high rates of return. When we think about Enzolytics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 190 K. Net Loss for the year was (57.28 K) with profit before overhead, payroll, taxes, and interest of 52.81 K. | |
| Latest headline from cnbc.com: Healthy Returns Botox, Trulicity among 15 drugs added to Medicare price negotiations |
- Analyzing Enzolytics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enzolytics' stock is overvalued or undervalued compared to its peers.
- Examining Enzolytics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enzolytics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enzolytics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enzolytics' pink sheet. These opinions can provide insight into Enzolytics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Enzolytics Pink Sheet analysis
When running Enzolytics' price analysis, check to measure Enzolytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzolytics is operating at the current time. Most of Enzolytics' value examination focuses on studying past and present price action to predict the probability of Enzolytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzolytics' price. Additionally, you may evaluate how the addition of Enzolytics to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stocks Directory Find actively traded stocks across global markets |